Incidence and PFS of genetic markers
| Genetic alteration . | GClb . | VenG . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Incidence . | 24m PFS, % . | mPFS, m . | HR . | 95% CI . | P . | Incidence . | 24m PFS, % . | mPFS, m . | HR . | 95% CI . | P . | |
| del(17p) | 14/208 | 23.1 | 15.1 | 7.41 | 3.36-16.32 | <.01 | 17/210 | 64.7 | 29 | 4.19 | 1.55-11.33 | <.01 |
| del(11q) | 38/208 | 41.3 | 18 | 3.44 | 1.8-6.6 | <.01 | 36/210 | 91.2 | NR | 0.94 | 0.29-3.05 | .92 |
| +12 | 40/208 | 55.6 | NR | 2.22 | 1.13-4.35 | .02 | 36/210 | 100 | NR | NE | NE | NE |
| Normal | 42/208 | 82.1 | NR | 0.89 | 0.38-2.06 | .79 | 50/210 | 87.2 | NR | 1.54 | 0.61-3.89 | .36 |
| del(13q) | 74/208 | 81 | NR | NE | NE | NE | 71/210 | 88.4 | NR | NE | NE | NE |
| NOTCH1 | 48/210 | 59.2 | 23.4 | 1.74 | 1.06-2.88 | .03 | 47/211 | 85.8 | NR | 1.57 | 0.69-3.58 | .28 |
| SF3B1 | 39/210 | 56.7 | NR | 1.52 | 0.88-2.62 | .13 | 29/211 | 92.3 | NR | 0.79 | 0.24-2.6 | .69 |
| ATM | 30/210 | 50.8 | 31.1 | 1.77 | 0.99-3.18 | .06 | 23/211 | 95.5 | NR | 0.61 | 0.14-2.56 | .5 |
| TP53 | 19/210 | 36.8 | 19.8 | 2.74 | 1.50-5.00 | <.01 | 23/211 | 72.7 | NR | 3.08 | 1.31-7.25 | .01 |
| XPO1 | 17/210 | 64.7 | NR | 1.03 | 0.47-2.24 | .94 | 9/211 | 87.5 | NR | 1.25 | 0.17-9.26 | .83 |
| RPS15 | 12/210 | 57.1 | NR | 1.167 | 0.47-2.88 | .75 | 11/211 | 81.8 | NR | 1.34 | 0.32-5.64 | .69 |
| POT1 | 11/210 | 90.9 | NR | 0.41 | 0.1-1.67 | .21 | 10/211 | 100 | NR | NE | NE | NE |
| BRAF | 9/210 | 57.1 | 24.5 | 1.75 | 0.64-4.79 | .28 | 9/211 | 100 | NR | NE | NE | NE |
| NFKBIE | 11/210 | 70.7 | NR | 0.82 | 0.26-2.6 | .73 | 6/211 | 100 | NR | NE | NE | NE |
| BIRC3 | 9/210 | 14.3 | 16.8 | 4.03 | 1.73-9.37 | <.01 | 7/211 | 85.7 | NR | 1.1 | 0.15-8.13 | .92 |
| EGR2 | 10/210 | 66.7 | NR | 1.39 | 0.51-3.82 | .52 | 5/211 | 80 | NR | 2.79 | 0.66-11.78 | .16 |
| MYD88 | 7/210 | 100 | NR | NE | NE | NE | 3/211 | 100 | NR | NE | NE | NE |
| Unmutated IGHV | 123/208 | 51 | 25.6 | 3.45 | 1.95-6.1 | <.01 | 121/200 | 89.4 | NR | 1.16 | 0.51-2.62 | .73 |
| Mutated IGHV | 83/208 | 85.6 | NR | NE | NE | NE | 76/200 | 90.3 | NR | NE | NE | NE |
| Genetic alteration . | GClb . | VenG . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Incidence . | 24m PFS, % . | mPFS, m . | HR . | 95% CI . | P . | Incidence . | 24m PFS, % . | mPFS, m . | HR . | 95% CI . | P . | |
| del(17p) | 14/208 | 23.1 | 15.1 | 7.41 | 3.36-16.32 | <.01 | 17/210 | 64.7 | 29 | 4.19 | 1.55-11.33 | <.01 |
| del(11q) | 38/208 | 41.3 | 18 | 3.44 | 1.8-6.6 | <.01 | 36/210 | 91.2 | NR | 0.94 | 0.29-3.05 | .92 |
| +12 | 40/208 | 55.6 | NR | 2.22 | 1.13-4.35 | .02 | 36/210 | 100 | NR | NE | NE | NE |
| Normal | 42/208 | 82.1 | NR | 0.89 | 0.38-2.06 | .79 | 50/210 | 87.2 | NR | 1.54 | 0.61-3.89 | .36 |
| del(13q) | 74/208 | 81 | NR | NE | NE | NE | 71/210 | 88.4 | NR | NE | NE | NE |
| NOTCH1 | 48/210 | 59.2 | 23.4 | 1.74 | 1.06-2.88 | .03 | 47/211 | 85.8 | NR | 1.57 | 0.69-3.58 | .28 |
| SF3B1 | 39/210 | 56.7 | NR | 1.52 | 0.88-2.62 | .13 | 29/211 | 92.3 | NR | 0.79 | 0.24-2.6 | .69 |
| ATM | 30/210 | 50.8 | 31.1 | 1.77 | 0.99-3.18 | .06 | 23/211 | 95.5 | NR | 0.61 | 0.14-2.56 | .5 |
| TP53 | 19/210 | 36.8 | 19.8 | 2.74 | 1.50-5.00 | <.01 | 23/211 | 72.7 | NR | 3.08 | 1.31-7.25 | .01 |
| XPO1 | 17/210 | 64.7 | NR | 1.03 | 0.47-2.24 | .94 | 9/211 | 87.5 | NR | 1.25 | 0.17-9.26 | .83 |
| RPS15 | 12/210 | 57.1 | NR | 1.167 | 0.47-2.88 | .75 | 11/211 | 81.8 | NR | 1.34 | 0.32-5.64 | .69 |
| POT1 | 11/210 | 90.9 | NR | 0.41 | 0.1-1.67 | .21 | 10/211 | 100 | NR | NE | NE | NE |
| BRAF | 9/210 | 57.1 | 24.5 | 1.75 | 0.64-4.79 | .28 | 9/211 | 100 | NR | NE | NE | NE |
| NFKBIE | 11/210 | 70.7 | NR | 0.82 | 0.26-2.6 | .73 | 6/211 | 100 | NR | NE | NE | NE |
| BIRC3 | 9/210 | 14.3 | 16.8 | 4.03 | 1.73-9.37 | <.01 | 7/211 | 85.7 | NR | 1.1 | 0.15-8.13 | .92 |
| EGR2 | 10/210 | 66.7 | NR | 1.39 | 0.51-3.82 | .52 | 5/211 | 80 | NR | 2.79 | 0.66-11.78 | .16 |
| MYD88 | 7/210 | 100 | NR | NE | NE | NE | 3/211 | 100 | NR | NE | NE | NE |
| Unmutated IGHV | 123/208 | 51 | 25.6 | 3.45 | 1.95-6.1 | <.01 | 121/200 | 89.4 | NR | 1.16 | 0.51-2.62 | .73 |
| Mutated IGHV | 83/208 | 85.6 | NR | NE | NE | NE | 76/200 | 90.3 | NR | NE | NE | NE |
Absolute numbers of patients harboring mutations are provided for each treatment group with corresponding median PFS (mPFS) and 24-month PFS (24m PFS). For genetic aberrations, hazard ratio (HR), 95% confidence interval (95% CI) and P value are calculated vs del(13q), for gene mutations and IGHV status presence vs absence.
NE, not evaluable because of no event/no comparator; NR, not reached.